Clinical trials: SARSCoV2 Convalescent Plasma
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health
COVID19, Coronavirus Infection
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements.
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases
- Trial name
- NCT04376034
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- West Virginia University
COVID, SARSCoV2 Convalescent Plasma
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19…
- Trial name
- NCT04374370
- Testing
- SARSCoV2 Convalescent Plasma
- Where
- United States
- Sponsor
- AdventHealth
COVID, Sars-CoV2
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Trial name
- NCT04445207
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Jonathan Gerber
COVID
Convalescent Plasma vs. Standard Plasma for COVID-19
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat…
- Trial name
- NCT04344535
- Testing
- Convalescent Plasma, Standard Donor Plasma
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Stony Brook University
Sars-CoV2, Covid-19
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality.
- Trial name
- NCT04425837
- Testing
- SARS-CoV-2 convalescent plasma treatment, Standard care
- Where
- Colombia
- Volunteers
- 236 people
- Sponsor
- Fundación Santa Fe de Bogota
Covid19
Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort
The coronavirus disease 2019 (COVID-19) viral pneumonia is now a worldwide pandemic caused by the Severe acute respiratory virus coronavirus 2 (SARS-CoV-2).
- Trial name
- CORIPLASM (NCT04345991)
- Testing
- Transfusion of COVID-19 convalescent plasma
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
COVID-19
Convalescent Plasma Therapy - Zurich Protocol
This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and…
- Trial name
- CPT-ZHP (NCT04869072)
- Testing
- Convalescent plasma
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
COVID-19 Convalescent Plasma Treatment
Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness
A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness.
- Trial name
- EPIC-19 (NCT04642014)
- Testing
- COVID-19 convalescent plasma treatment
- Where
- Poland
- Volunteers
- 396 people
- Sponsor
- Wroclaw Medical University
Coronavirus
Convalescent Plasma to Limit Coronavirus Associated Complications
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
- Trial name
- NCT04325672
- Testing
- Convalescent Plasma
- Sponsor
- Mayo Clinic
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
COVID, Infectious Disease
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized…
- Trial name
- (ESCAPE) (NCT04361253)
- Testing
- High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Brigham and Women's Hospital
COVID-19, Severe Acute Respiratory Syndrome (SARS)
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
The goal of this study is to evaluate the safety and effectiveness of Coronavirus-90 (COVID-19) convalescent plasma for the treatment of COVID-19.
- Conditions
- COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- ABACCuS (NCT04432272)
- Testing
- COVID-19 convalescent plasma
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Corewell Health East
Covid19
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid…
- Trial name
- NCT04956445
- Where
- 2 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tulane University
COVID-19, Convalescent Plasma
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19.
- Conditions
- COVID-19, Convalescent Plasma, SARS-CoV-2, Pneumonia
- Trial name
- NCT05077930
- Testing
- Convalescent plasma, Standard of care
- Where
- Brazil
- Volunteers
- 38 people
- Sponsor
- Tânia Portella Costa
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
COVID-19
Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support
The COVID-19 pandemic has been spreading continuously, and in Brazil, until August 18, 2020, there have been more than 3,359,000 cases with more than 108,536 deaths, with daily increases.
- Trial name
- NCT04528368
- Testing
- Convalescent plasma
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- D'Or Institute for Research and Education
COVID-19, SARS-CoV-2 Infection
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19
- Conditions
- COVID-19, SARS-CoV-2 Infection, Severe Acute Respiratory Syndrome Coronavirus 2
- Trial name
- NCT04516811
- Testing
- COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
- Where
- 2 sites in South Africa
- Volunteers
- 102 people
- Sponsor
- South African National Blood Service